logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Malignant How Bad Policy And Bad Evidence Harm People With Cancer Vinayak K Prasad

  • SKU: BELL-10944150
Malignant How Bad Policy And Bad Evidence Harm People With Cancer Vinayak K Prasad
$ 31.00 $ 45.00 (-31%)

4.4

82 reviews

Malignant How Bad Policy And Bad Evidence Harm People With Cancer Vinayak K Prasad instant download after payment.

Publisher: Johns Hopkins University Press
File Extension: PDF
File size: 3.2 MB
Pages: 304
Author: Vinayak K. Prasad
ISBN: 9781421437637, 1421437635
Language: English
Year: 2020

Product desciption

Malignant How Bad Policy And Bad Evidence Harm People With Cancer Vinayak K Prasad by Vinayak K. Prasad 9781421437637, 1421437635 instant download after payment.

Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel―but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which
• promote novel cancer therapies long before credible data are available to support such treatment; and
• exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars.
Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration.
This is a book about how the actions of human beings―our policies, our standards of evidence, and our drug regulation―incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says,
• more cancer clinical trials should measure outcomes that actually matter to people with cancer;
• patients on those trials should look more like actual global citizens;
• we need drug regulators to raise, not perpetually lower, the bar for approval; and
• we need unbiased patient advocates and experts.
This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer―and how we can avoid repeating the policy and practice mistakes of the past.

Related Products